Exagen (NASDAQ:XGN) Azioni

Exagen

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Exagen Inc

Real Estate

FCPT

Corners Property Trust Acquires A Chuy's Property For $2.9M

Activist <a href="https://www.benzinga.com/topic/dan-loeb" target="_blank" rel="noreferrer noopener">investor </a><a href="https://www.benzinga.com/topic/dan-loeb" target="_blank" rel="noreferrer noopener">Dan Loeb</a>‘s Third Point LLC held 1.78 million shares in Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/news/large-cap/25/01/43195763/dan-loebs-third-point-capitalizes-on-tsms-ai-expansion" target="_blank" rel="noreferrer noopener">as of December 2024</a>.
The chip manufacturer&#8217;s share price dipped nearly 27 year to date. Compared that to VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>), which fell over 23%, and the S&amp;P 500's year-to-date decline of roughly 12.1%.
Earnings &amp; Other Notable Events:
<ul>
<li>On April 17, Taiwan Semiconductor reported first-quarter net sales of $25.53 billion (839.25 billion New Taiwanese Dollars). That&#8217;s up 41.6% year-over-year (Y/Y), topping the<a href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" target="_blank" rel="noreferrer noopener"> analyst consensus estimate of $23.92 billion</a>.</li>
<li>The demand for advanced&nbsp;processor node technologies for artificial intelligence applications fueled the result.</li>
<li>Taiwan Semiconductor&nbsp;guided for second-quarter&nbsp;2025 revenue of $28.4 billion to $29.2 billion versus the $26.79<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">&nbsp;billion analyst estimate</a>. It expects a gross margin of 57% to 59% and operating profit margins of 47% to 49%.</li>
<li>Taiwan Semiconductor&#8217;s CFO said, so far, there has been no noticeable shift <a href="https://www.benzinga.com/markets/25/04/44881525/tsmc-confident-amid-trump-tariff-turmoil-ceo-cc-wei-says-no-change-in-customer-behavior-despite-nvidia-h20-chip-curbs" target="_blank" rel="noreferrer noopener">in customer behavior in response</a> to U.S. tariffs.</li>
<li>Notably, China's new rule reportedly&nbsp;exempts chips designed&nbsp;by U.S. companies but manufactured in Taiwan from its 125% retaliatory tariffs. This rule has also exempted TSMC.</li>
<li>Also, the company disclosed in its 2024 annual report that the&nbsp;U.S. semiconductor technology&nbsp;embargo challenged its ability to ensure <a href="https://www.benzinga.com/government/regulations/25/04/44895326/taiwan-semiconductor-confronts-challenges-of-us-chips-sanction-on-china" target="_blank" rel="noreferrer noopener">complete compliance with the rules</a>.</li>
<li>Goldman Sachs&nbsp;analyst&nbsp;Kinger Lau, CFA, said delisting fears for Chinese American Depositary Receipts (ADRs) are rising again, driven by escalating trade tensions and new policy guidance from U.S. officials, including President&nbsp;Donald Trump‘s America First Investment Policy and Treasury Secretary&nbsp;Scott Bessent&#8216;s statement that &#8220;everything is on the table&#8221; <a href="https://www.benzinga.com/government/regulations/25/04/44868280/us-listed-chinese-stocks-face-250-billion-forced-selling-risk-as-delisting-fears-emerge-what-investors-need-to-know" target="_blank" rel="noreferrer noopener">in the response to China&#8217;s retaliatory tariffs</a>.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44698171/trumps-tariff-push-sends-financials-lower-loebs-portfolio-take-a-hit" target="_blank" rel="noreferrer noopener">Tariffs Test Loeb's Financial Picks: Third Point Adjusts Bets As Markets Brace For Economic Blowback</a></li>
</ul>
Image: Shutterstock

Tech

Dan Loeb's Bet On Taiwan Semiconductor Looks Strong As Q1 Results Top Expectations

WIIM

Meiwu Technology shares are trading higher after the company announced it regained Nasdaq compliance.

XAIR

Beyond Air shares are trading higher after the company announced its NeuroNOS subsidiary was granted an FDA Orphan Drug Designation.

FORWARD-LOOKING NON-GAAP MEASURES.&nbsp;The following table reconciles Net Income per Common Share - Fully Diluted guidance to FFO per Common Share and OP Unit - Fully Diluted guidance and Normalized FFO per Common Share and OP Unit - Fully diluted guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(Unaudited)</td>
<td colspan="1" rowspan="1">
Second Quarter
2025
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">
Full Year
2025
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income per Common Share</td>
<td colspan="1" rowspan="1">$0.40 to $0.46</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.97 to $2.07</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and amortization</td>
<td colspan="1" rowspan="1">0.26</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1.04</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FFO per Common Share and OP Unit - Fully Diluted</td>
<td colspan="1" rowspan="1">$0.66 to $0.72</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3.01 to $3.11</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Normalized FFO per Common Share and OP Unit - Fully Diluted</td>
<td colspan="1" rowspan="1">$0.66 to $0.72</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3.01 to $3.11</td>
</tr>
</tbody>
</table>
</figure>

News

Guidance

Equity Lifestyle Props Sees Q2 Normalized FFO $0.66-$0.72; FY25 Normalized FFO $3.01-$3.11

ZION

Zions Bancorp shares are trading lower after the company reported Q1 financial results and missed its EPS and sales estimates.

Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) reported quarterly earnings of $0.83 per share which met the analyst consensus estimate. This is a 6.41 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $387.33 million which missed the analyst consensus estimate of $398.72 million by 2.85 percent. This is a 0.20 percent increase over sales of $386.57 million the same period last year.

Earnings

Earnings Misses

Equity Lifestyle Props Q1 FFO $0.83, Inline, Sales $387.33M Miss $398.72M Estimate

CALX

Calix shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates. Additionally, the company announced an authorized increase to its stock repurchase program.

Calix shares are trading higher following strong Q1 earnings and upbeat Q2 guidance.

Earnings Beats

FLXS

Flexsteel Industries Q3 2025 Adj EPS $1.13 Beats $0.88 Estimate, Sales $113.97M Beats $111.94M Estimate

Shenzhen, China, April 21, 2025 (GLOBE NEWSWIRE) -- Meiwu Technology Company Limited ("WNW" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) announced today that it received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company's ordinary shares, no par value each (the "Ordinary Shares") to maintain a minimum bid price of $1.00 per share.
The Nasdaq staff made this determination of compliance after the closing bid price of the Company's Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from April 1, 2025, to April 14, 2025. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.

Meiwu Technology Company Regains Compliance With Nasdaq

Calix Sees Q2 Adj. EPS $0.18-$0.24 vs $0.15 Est., Revenue $221M-$227M vs $210.527M Est.

Clearwater Will Deliver Industry's First Unified, Cloud-Native Front-to-Back Platform for Institutional Investors
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclearwateranalytics.com%2F%3Futm_medium%3Dthird-party%26utm_source%3Dpress-release%26utm_campaign%3Dbw-enfusionclose&amp;esheet=54241058&amp;newsitemid=20250421999466&amp;lan=en-US&amp;anchor=Clearwater+Analytics&amp;index=1&amp;md5=da67dbce39b66fd5c79f99f56ecc261e">Clearwater Analytics</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>), the most comprehensive technology platform for investment management, today announced the successful completion of its acquisition of Enfusion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>), a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund sectors, in a deal valued at approximately $1.5 billion.
This strategic combination positions Clearwater as the industry's first single-instance, multi-tenant, cloud-native platform to unify front, middle, and back-office investment operations. By integrating portfolio and order management, IBOR, risk, accounting, and client reporting into one seamless solution, Clearwater is replacing the fragmented legacy model with a modern platform that empowers faster decision-making and operational clarity across asset classes and geographies.
"The close of the Enfusion acquisition marks a major milestone—not just for Clearwater, but for the entire investment management industry," said Sandeep Sahai, Chief Executive Officer of Clearwater Analytics. "By combining Enfusion's strong front-office capabilities with our established middle and back-office solutions, we are accelerating our journey towards a fully integrated, cloud-native front-to-back investment management platform. This combination will eliminate costly data handoffs and inefficiencies stemming from fragmented workflows, empowering our clients to make faster, data-driven decisions with complete confidence in their data."
"I'm immensely proud of what the Enfusion team has achieved and the shareholder value we delivered. Enfusion's focus on innovation and client requirements created a world-class disruptive technology platform, fundamentally changing how our clients execute their operational workflows, implement investment strategies, manage portfolios, and optimize data insights," said Oleg Movchan, former CEO of Enfusion. "By joining forces with Clearwater, we're opening up amazing possibilities for the next wave of innovation in investment technology. I couldn't be more optimistic about how this combination will benefit our clients and transform the industry."
Today's institutional investors—asset managers, insurers, pensions, endowments, and sovereign funds—face increasing complexity across portfolios, geographies, and asset classes. Many still rely on outdated systems that silo data and delay insight. The expanded Clearwater platform will address these challenges by offering:
<ul>
<li>Seamless integration across front, middle, and back-office workflows</li>
<li>A single security master and data model for consistent, real-time views of positions, performance, and risk</li>
<li>An open architecture that connects to a growing ecosystem of partners and capabilities</li>
</ul>
"Enfusion adds proven front-office depth to the Clearwater platform, giving our clients real-time access to portfolio and order management, IBOR, risk, and reporting—all in one system," said Neal Pawar, President, Head of Asset Management at Clearwater Analytics and former Chief Operating Officer at Enfusion. "The operational benefits are immediate: no batch processing, no manual reconciliation, and no duplication of data. Clients now have a shared, live view of their portfolios and operations—enabling faster execution, stronger risk oversight, and a platform that evolves with them. This is the new foundation for institutional investment technology and operations."
Clearwater's growth in asset management—its largest market segment—is expected to accelerate, with Enfusion's strength in the hedge fund space and the ability to integrate Enfusion's front office capabilities with Clearwater's middle and back office. This will result in a meaningful expansion of Clearwater's Total Addressable Market.
The acquisition also significantly expands Clearwater's international presence. Enfusion generates 38% of its revenue from Europe and Asia, supported by strong teams in London, Mumbai, Bangalore, Singapore, and Hong Kong. Clearwater will now serve clients from key global hubs including Boise, New York, Edinburgh, and New Delhi, providing localized support and delivery at scale.

CWAN

ENFN

Clearwater Analytics Successfully Completes Its Acquisition Of Enfusion In Deal Valued At ~$1.5B

2025 Financial Guidance
The Company forecasts 2025 revenue in the range of $2.140 billion to $2.240 billion, representing growth of 1.5% to 6.2% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $378.0 million to $402.0 million. Additionally, full year 2025 EBITDA is expected in the range of $462.0 million to $492.0 million. Based on forecasted 2025 revenue of $2.140 billion to $2.240 billion and GAAP net income of $378.0 million to $402.0 million, diluted earnings per share (GAAP) is forecasted in the range of $12.26 to $13.04. This guidance assumes a full year 2025 tax rate of 15.5% to 16.5%, interest income of $15.8 million, and 30.8 million diluted shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after March 31, 2025.

MEDP

Medpace Sees FY25 EPS $12.26-$13.04 Vs $12.27 Est.; Revenue $2.14B-$2.24B Vs $2.149B Est.

Two prominent Fed voiced issued strong public defenses of the central bank&#8217;s independence on Monday, calling out President Donald Trump&#8216;s attacks on Chair Jerome Powell as politically <a href="https://www.benzinga.com/topic/jerome-powell">dangerous and economically destabilizing.</a>
Speaking Monday on CNBC, Richard Fisher, former president of the Dallas Fed, warned that Trump's repeated attacks on Powell could inflict serious long-term damage on the credibility of the Federal Reserve and the broader U.S. economy.
"The one thing you don't want to have happen is for the Fed to become politicized," Fisher said.
Fisher added that even if Trump could fire Powell, which remains legally uncertain, it would be a self-defeating move.
"I don't think it's in the president's interest to sack him. The markets would react extremely negatively," he said.
Fisher also highlighted that current uncertainty has already paralyzed corporate decision-making, referencing companies like United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), which recently offered dual earnings forecasts due to macroeconomic unpredictability.
"I think the president, frankly, is undermining his own case." "No business can make a decision here," Fisher said. "That uncertainty has been generated by the executive branch."
When asked whether Trump could legally demote or remove Powell, Fisher pointed to historical precedent—most notably in 1979, when President Jimmy Carter reassigned then-Fed Chair G. William Miller to Treasury Secretary after a period of poor economic performance and appointed Paul Volcker in his place. 
"I hope it doesn't come to push and shove," he said. "If it does, we're going to see further spread widening, higher interest rates and pressure that damages long-term confidence in the economy."
Fisher also pushed back on the assumption that Fed rate cuts would lower market interest rates, pointing out that recent episodes of easing were followed by yield spikes in longer-term bonds.
"After they cut 50 basis points and then did three more cuts, yields went up—not down. The 10-year rose by 100 basis points," Fisher said. "So even if you force cuts, the market may not respond how you think."
Ultimately, Fisher painted a picture of a market hamstrung by political volatility and a Fed cornered by noise from the White House.
&#8220;Forget about the stock market, the FED will always act if the credit markets become dysfunctional.&#8221;
<h3 class="wp-block-heading">Goolsbee: Interference Means &#8216;Higher Inflation, Worse Growth&#8217;</h3>
Echoing Fisher's concerns, Austan Goolsbee, President of the Federal Reserve Bank of Chicago, said earlier on <a href="https://www.cnbc.com/2025/04/21/chicago-feds-goolsbee-says-fed-independence-is-critically-important-for-its-inflation-fight.html">CNBC's Squawk Box</a> that interfering with the Fed's independence would erode the institution's credibility and lead to long-term economic pain.
"Fed independence is critically important," Goolsbee said. "When there is interference over the long run, it's going to mean higher inflation, worse growth and higher unemployment."
Although Goolsbee declined to comment directly on Trump's statements, his message was clear: monetary credibility depends on political neutrality, especially when inflation-fighting resolve is needed.
"Just look at the countries where they don't have Fed independence. Inflation is higher, unemployment is higher, growth is worse," he added.
U.S. financial markets came under heavy pressure Monday, with stocks, bonds and the dollar falling in unison, a rare and unsettling signal of deepening investor distrust.
The U.S. Dollar Index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), slid to its lowest level since April 2022.
The S&amp;P 500, mirrored by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), sank 3.3% in one of its steepest single-day drops of the year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44903750/gold-price-soars-to-record-highs-eyes-best-2-month-rally-since-2011-on-blockbuster-etf-buying">Gold Price Soars To Record Highs, Eyes Best 2-Month Rally Since 2011 On Blockbuster ETF Buying</a></li>
</ul>
Photo: RozenskiP / Shutterstock.com

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Top Fed Voices Defend Powell, Slam Trump's Attack On Central Bank Independence

Calix Q1 2025 Adj. EPS $0.19 Beats $0.13 Estimate, Sales $220.242M Beat $206.976M Estimate

Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) reported quarterly earnings of $3.67 per share which beat the analyst consensus estimate of $3.06 by 19.93 percent. This is a 14.69 percent increase over earnings of $3.20 per share from the same period last year. The company reported quarterly sales of $558.57 million which beat the analyst consensus estimate of $527.15 million by 5.96 percent. This is a 9.30 percent increase over sales of $511.04 million the same period last year.

Medpace Hldgs Q1 EPS $3.67 Beats $3.06 Estimate, Sales $558.57M Beat $527.15M Estimate

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) reported quarterly earnings of $0.67 per share which missed the analyst consensus estimate of $0.81 by 17.28 percent.

AZZ Q4 2025 GAAP EPS $0.67 Misses $0.81 Estimate

Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) stock traded lower on Monday after Huawei announced it was preparing a new artificial intelligence (AI) chip as an alternative <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44906106/whats-going-on-with-nvidia-stock-monday-2">to Nvidia&#8217;s H20 line.</a>
The Details: Broadcom, along with the broader semiconductor industry, is moved lower Monday following Huawei&#8217;s announcement. Huawei&nbsp;intends to start delivering its advanced 910C AI chip to customers in China as early as next month, according to Reuters.
The chip matches the performance of Nvidia's H100 by combining two 910B processors into a single unit using advanced integration techniques. President Donald Trump's administration <a href="https://www.benzinga.com/news/global/25/04/44828742/nvidia-stock-is-tumbling-after-hours-heres-why">recently implemented licensing</a> requirements for selling Nvidia's H20 and <a href="https://www.benzinga.com/news/25/04/44900227/amd-stock-drops-amid-ai-chip-export-ban-whats-going-on">select AMD chips</a> to China.
Broadcom shares may be trading lower as investors evaluate the competitive risk from Huawei and its potential impact on Broadcom's presence in the Chinese market. Ongoing concerns about tariffs and trade restrictions may also be weighing on sentiment across the chip sector.
AVGO Price Action: Broadcom shares closed 2.80% lower at $166.21 on Monday, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Related Link: • <a href="https://www.benzinga.com/25/04/44908743/mp-materials-stock-is-tumbling-monday-heres-why-investors-are-dumping-shares">MP Materials Stock Is Tumbling Monday: Here&#8217;s Why Investors Are Dumping Shares</a>
Photo: Shutterstock

Movers

AVGO

What's Going On With Broadcom Shares Monday?

Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) reported quarterly earnings of $1.13 per share which missed the analyst consensus estimate of $1.17 by 3.42 percent. The company reported quarterly sales of $795.000 million which missed the analyst consensus estimate of $797.069 million by 0.26 percent. This is a 7.14 percent increase over sales of $742.000 million the same period last year.

Zions Bancorp Q1 2025 GAAP EPS $1.13 Misses $1.17 Estimate, Sales $795.000M Miss $797.069M Estimate

Press Releases

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

Exagen Inc. Reports Third Quarter 2024 Results

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Health Care

General

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Analyst Ratings

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Comments

Exagen

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO